Related Experiment Video

Updated: Jul 5, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

European paediatric research and children's therapeutic needs. A trial review

C Pandolfini1, M Bonati

  • 1Laboratory for Mother and Child Health, Mario Negri Pharmacological Research Institute, Milan, Italy. pandolfini@marionegri.it

Acta Paediatrica (Oslo, Norway : 1992)
|May 21, 2008
PubMed

Insights

European paediatric drug research shows a significant gap between children's therapeutic needs and current research focus. The Paediatric Regulation aims to better align drug development with these essential needs.

Area of Science:

  • Paediatric pharmacology
  • Clinical trial analysis
  • European drug regulation

Background:

  • Paediatric drug therapy research is crucial for addressing children's specific health needs.
  • The European Medicines Agency (EMEA) established priority lists for paediatric medicinal products.

Purpose of the Study:

  • To assess the landscape of paediatric therapeutic research in Europe.
  • To evaluate the alignment of ongoing research with identified paediatric needs and EMEA priorities.

Main Methods:

  • Analysis of 379 ongoing and published paediatric drug therapy trials (2004-2007) across 27 EU countries.
  • Comparison of trial data with the EMEA priority list for paediatric studies.
  • Utilized data from the DEC-net paediatric trial register and two biomedical databases.

Main Results:

  • The majority of trials focused on infectious and parasitic diseases; however, only four of 25 EMEA priority conditions were significantly addressed.
  • Malignant diseases and asthma were the most common EMEA priority areas studied.
  • Ongoing research showed a better, though still limited, coverage of EMEA priority conditions compared to published trials.

Conclusions:

  • Despite ongoing paediatric research in Europe, a notable disconnect exists between therapeutic needs and research activities.
  • The European Paediatric Regulation is expected to foster research more closely aligned with children's actual medical requirements.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...